Back to discover

Protein / target

Tight junction protein 1

Encoded byTJP1Q07157Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Med-Quality Pocket
1
Research papers

Protein at a glance

Biological role

Cell adhesion molecule binding

Strongest disease association

Skin Diseases

Via encoding gene TJP1 · Genetic evidence · score 0.52

Research activity

Emerging research

1 papers · latest 2009

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

TJP1, TJP2, and TJP3 are closely related scaffolding proteins that link tight junction (TJ) transmembrane proteins such as claudins, junctional adhesion molecules, and occludin to the actin cytoskeleton.

View complete UniProt function annotation

TJP1, TJP2, and TJP3 are closely related scaffolding proteins that link tight junction (TJ) transmembrane proteins such as claudins, junctional adhesion molecules, and occludin to the actin cytoskeleton (PubMed:7798316, PubMed:9792688). Forms a multistranded TJP1/ZO1 condensate which elongates to form a tight junction belt, the belt is anchored at the apical cell membrane via interaction with PATJ (By similarity). The tight junction acts to limit movement of substances through the paracellular space and as a boundary between the compositionally distinct apical and basolateral plasma membrane domains of epithelial and endothelial cells. Necessary for lumenogenesis, and particularly efficient epithelial polarization and barrier formation (By similarity). Plays a role in the regulation of cell migration by targeting CDC42BPB to the leading edge of migrating cells (PubMed:21240187). Plays an important role in podosome formation and associated function, thus regulating cell adhesion and matrix remodeling (PubMed:20930113). With TJP2 and TJP3, participates in the junctional retention and stability of the transcription factor DBPA, but is not involved in its shuttling to the nucleus (By similarity). May play a role in mediating cell morphology changes during ameloblast differentiation via its role in tight junctions (By similarity)

Subcellular location

Cell membraneCell junction, tight junctionCell junctionCell junction, gap junctionCell projection, podosome
Domains and Gene Ontology detail (44)

Domains & features

PDZ 1PDZ 2PDZ 3SH3Guanylate kinase-likeZU5

Gene Ontology

  • Cadherens junction
  • Capical junction complex
  • Capical part of cell
  • Cbasolateral plasma membrane
  • Cbicellular tight junction
  • Ccell junction
  • Ccytoplasm
  • Ccytosol
  • Cgap junction
  • Cplasma membrane
  • Cpodosome
  • Cprotein-containing complex

1748 aa · 195 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProt · GOCell proliferation & survivalGOCell adhesionUniProt · GO
View supporting evidence

Cell migration

  • ·TJP1, TJP2, and TJP3 are closely related scaffolding proteins that link tight junction (…
  • ·positive regulation of cell migration

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Cell adhesion

  • ·TJP1, TJP2, and TJP3 are closely related scaffolding proteins that link tight junction (…
  • ·Cell junction, tight junction
  • ·Cell junction
  • ·Cell junction, gap junction

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TJP1

Gene-level evidence surfaced through the gene TJP1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Skin Diseases
0.52Moderately supported

Genetic evidence dominant · Open Targets 0.32

Alzheimer's Disease
0.46Limited support

Genetic evidence dominant · Open Targets 0.27

Tuberculosis
0.43Limited support

Genetic evidence dominant · Open Targets 0.26

Cataract
0.37Limited support

Genetic evidence dominant · Open Targets 0.23

Dengue
0.35Preliminary

Pathway evidence dominant · Open Targets 0.48 · no direct causal or clinical evidence

View evidence synthesis (5)
Skin DiseasesModerately supported
0.52
agreement 0.380.66
Genetic99%Literature1%

Open Targets aggregate 0.32 · 2 independent evidence families

Alzheimer's DiseaseLimited support
0.46
agreement 0.340.59
Genetic87%Literature13%RNA expression1%

Open Targets aggregate 0.27 · 3 independent evidence families

TuberculosisLimited support
0.43
agreement 0.290.57
Genetic97%Literature3%

Open Targets aggregate 0.26 · 2 independent evidence families

CataractLimited support
0.37
agreement 0.230.51
Genetic99%Literature1%

Open Targets aggregate 0.23 · 2 independent evidence families

DenguePreliminary
0.35
agreement 0.170.53
Pathway82%Literature18%

Open Targets aggregate 0.48 · 2 independent evidence families · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Dengue0.48
COVID-190.37
Skin Diseases0.32
Alzheimer's Disease0.27
Tuberculosis0.26
Cataract0.23

Tractability

Small moleculesEmerging

Feasibility evidence (med-quality pocket) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (database ubiquitination and half-life data) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Med-Quality PocketAB · UniProt loc high confAB · GO CC high confPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2009

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.